Figures S1, S2, S3, S4 from Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF
Year: 2023
Type: other
Abstract: Figure S1: pMEK and pERK suppression in KRAS mutant and BRAFV600E cells by dabrafenib or RAF709. Figure S2: pMEK and pERK suppression in NRAS mutant and BRAFV600E cells by dabrafenib or RAF709. Figure S3: Cell cycle and apoptotic effects of RAF709 in KRASmut cells. Figure S4: Antiproliferative activity of RAF709 in HPAFII cells.
Authors: Wenlin Shao, Yuji M. Mishina, Yun Feng, Giordano Caponigro, Vesselina G. Cooke, Stacy Rivera, Yingyun Wang, Fang Shen, Joshua M. Korn, Lesley A. Mathews Griner, Gisele Nishiguchi, Alice Rico, John Tellew, Jacob R. Haling, Robert Aversa, Valery Polyakov, Richard Zang, Mohammad Hekmat-Nejad, Payman Amiri, Mallika Singh, Nicholas Keen, Michael P. Dillon, Emma Lees, Savithri Ramurthy, William R. Sellers, Darrin D. Stuart
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361234490